Astria nabs preclinical OX40 atopic dermatitis drug for $15M upfront, prices $64M offering
Astria Therapeutics revealed it had licensed Ichnos Sciences’ lead candidate for atopic dermatitis for an upfront fee of $15 million before …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
